Market Exclusive

ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Entry into a Material Definitive Agreement

ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.

LILLY ELI & CO Exhibit
EX-99.1 2 d685541dex991.htm EX-99.1 EX-99.1 Exhibit 99.1         January 7,…
To view the full exhibit click here

About ELI LILLY AND COMPANY (NYSE:LLY)

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.

Exit mobile version